JPRN-UMIN000001325已完成2 期
Phase II study of Neoadjuvant Letrozole for Postmenopausal Women with Endocrine-responsive and Anthracycline non-responsive Breast Cancer (JBCRG-06) - JBCRG-06
Japan Breast Cancer Research Group (JBCRG)0 个研究点目标入组 0 人开始时间: 2008年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Unmanageable serious complications 2. HCV 3. Unmanageable diabetes 4. Suspicious infection with fever 5. Active double cancer 6. Inflammatory breast cancer 7. Bilateral breast cancer 8. 10. History of drug-hypersensitivity 9. Receiving continuous systematic steroids, estrogen and Raloxifene 10. Mental disease 11. Patient judged inappropriate for this study by the physicians
研究者
相似试验
已完成
2 期
Phase II study of Neoadjuvant Letrozole and Docetaxel for Postmenopausal, Endocrine-responsive and Anthracycline non-responsive Breast Cancer (JBCRG-05)JPRN-UMIN000001214Japan Breast Cancer Research Group (JBCRG)3
招募中
不适用
Phase II study of efficacy of letrozole in postmenopausal patients with endocrine-responsive, HER2-negative metastatic breast cancer resistant to exemestane or anastrozole.Metastatic breast cancerJPRN-UMIN000006667Setouchi Breast Comprehensive Support Organaization60
Unknown
2 期
Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenER Positive, HER2 Negative Breast CancerNCT01709370Organisation for Oncology and Translational Research45
已完成
2 期
Evaluation of efficacy of letrozole as a neoadjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive breast cancerBreast cancerJPRN-UMIN000003101Tohoku University Graduate School of Medicine30
暂停
2 期
Study of neoadjuvant Letrozole combined with standerd chemotherapy for postmenopausal women with Endocrine-responsive Breast Cancer(subject of stage2,3A)Postmenopausal, hormone-receptor positive and resectable primary breast cancerJPRN-UMIN000002447iigata Cancer Center Hospital80